Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

Intravascular large B-cell lymphoma (IVLBCL) is a rare type of non-Hodgkin’s lymphoma. Its symptoms can vary, making it difficult to diagnose. The outlook for people with IVLBCL is typically poor.

Tezepelumab is superior to currently used treatment because it blocks thymic stromal lymphopoietin (TSLP) - an upstream modulator of multiple inflammatory pathways, instead of just targeting type ...